{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:27:26Z","timestamp":1768552046088,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[1998,9,1]],"date-time":"1998-09-01T00:00:00Z","timestamp":904608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypercalcemia represents one of the important paraneoplastic syndromes affecting morbidity and mortality of cancer patients. We and others have demonstrated that vitamin D analogs with little calcemic activities suppress the transcription of the parathyroid hormone-related peptide (PTHrP) gene, a major humor responsible for cancer hypercalcemia, and thereby prevent the development of hypercalcemic syndrome. The present study was undertaken: to compare the therapeutic efficacy of a vitamin D analog, 22-oxa-1,25-dihydroxyvitamin D3 (OCT), and a bisphosphonate (disodium 3-amino-1-hydroxypropylidene-1,1-bisphosphonate pentahydrate [AHPrBP]), an inhibitor of osteoclastic bone resorption, on cancer-induced hypercalcemia; and to see if the effect could be enhanced by combination treatment, using a nude mouse model implanted with a human pancreas carcinoma (FA-6). After a single intravenous administration, OCT (5 \u03bcg\/kg of body weight [BW]) was as effective as AHPrBP (10 mg\/kg of BW) in lowering blood ionized calcium levels in tumor-bearing nude mice, and their combination further enhanced the therapeutic effect. Although AHPrBP lost its efficacy after repeated injections, OCT was still effective after the third administration. The therapeutic effect of OCT in cancer hypercalcemia was observed in four other human tumors, including another pancreas carcinoma (PAN-7), two squamous cell carcinomas of the lung (KCC-C1 and LC-6), and a squamous carcinoma of the pharynx (PHA-1), all of which elaborated PTHrP into the circulation. Treatment with OCT resulted in a decrease in circulating PTHrP levels by approximately 50% in two representative models. However, the mechanism underlying the antihypercalcemic effect of OCT seemed complex, involving inhibition of PTHrP production, suppression of excessive bone resorption, and an antitumor activity. OCT also markedly inhibited the body weight loss with tumor growth, while AHPrBP, which exhibited a similar antihypercalcemic effect, was less effective than OCT in preventing cachexia. The anticachectic activity of their combination did not exceed that of OCT alone, suggesting a hypercalcemia-dependent as well as an independent mechanism of cancer cachexia. It is concluded that OCT may be useful, either as a single agent or in combination with bisphosphonates, for the treatment of cancer-associated hypercalcemia and cachexia.<\/jats:p>","DOI":"10.1359\/jbmr.1998.13.9.1378","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:05:00Z","timestamp":1146096300000},"page":"1378-1383","source":"Crossref","is-referenced-by-count":15,"title":["Effect of Combination Treatment with a Vitamin D Analog (OCT) and a Bisphosphonate (AHPrBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia"],"prefix":"10.1093","volume":"13","author":[{"given":"Koichi","family":"Endo","sequence":"first","affiliation":[{"name":"Pharmaceutical Research Laboratory, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Katsumata","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratory, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, National Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Kubodera","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Laboratory, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamio","family":"Teramoto","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoji","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Geriatric Research, National Institute for Longevity Sciences, Aichi, Japan"},{"name":"Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuro","family":"Ogata","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020713274664000_bib1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM198809013190906","article-title":"Humoral hypercalcemia of cancer: Identification of a novel parathyroid hormone-like peptide","volume":"319","author":"Broadus","year":"1988","journal-title":"N Engl J Med"},{"key":"2024020713274664000_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bjc.1991.80","article-title":"Cancer cachexia","volume":"63","author":"Tisdale","year":"1991","journal-title":"Br J Cancer"},{"key":"2024020713274664000_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0092-8674(93)90243-J","article-title":"Through thick and thin: Wasting, obesity, and TNF\u03b1","volume":"73","author":"Spiegelman","year":"1993","journal-title":"Cell"},{"key":"2024020713274664000_bib4","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1172\/JCI115767","article-title":"Evidence for the involvement of interleukin 6 in experimental cancer cachexia","volume":"89","author":"Strassmann","year":"1992","journal-title":"J Clin Invest"},{"key":"2024020713274664000_bib5","first-page":"6656","article-title":"Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor","volume":"51","author":"Mori","year":"1991","journal-title":"Cancer Res"},{"issue":"Suppl","key":"2024020713274664000_bib6","first-page":"523","article-title":"Bisphosphonates: History and experimental basis","volume":"8","author":"Fleisch","year":"1987","journal-title":"Bone"},{"key":"2024020713274664000_bib7","doi-asserted-by":"crossref","first-page":"32693","DOI":"10.1016\/S0021-9258(18)31690-9","article-title":"Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide gene in vivo","volume":"269","author":"Endo","year":"1994","journal-title":"J Biol Chem"},{"key":"2024020713274664000_bib8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1172\/JCI116475","article-title":"A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo","volume":"91","author":"Haq","year":"1993","journal-title":"J Clin Invest"},{"key":"2024020713274664000_bib9","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1248\/cpb.34.4410","article-title":"Synthetic studies of vitamin D analogues. VIII. Synthesis of 22-oxavitamin D3 analogues","volume":"34","author":"Murayama","year":"1986","journal-title":"Chem Pharmacol Bull"},{"key":"2024020713274664000_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1507\/endocrj1954.36.75","article-title":"The tumor cells (FA-6) established from a pancreatic cancer associated with humoral hypercalcemia of malignancy: A simultaneous production of parathyroid hormone-like activity and transforming growth factor activity","volume":"36","author":"Nagata","year":"1989","journal-title":"Endocrinol Jpn"},{"key":"2024020713274664000_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0304-3835(93)90053-C","article-title":"Establishment of lung cancer cell line producing parathyroid hormone-related protein","volume":"74","author":"Ichinose","year":"1993","journal-title":"Cancer Lett"},{"key":"2024020713274664000_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00300241","article-title":"Responsiveness of human cancer\/nude mouse to antitumor agents in a model using clinically equivalent doses","volume":"24","author":"Tashiro","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024020713274664000_bib13","first-page":"1322","article-title":"Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: Evidence for elevated levels in plasma from patients with adult T-cell leukemia\/lymphoma and B-cell lymphoma","volume":"79","author":"Ikeda","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713274664000_bib14","doi-asserted-by":"crossref","first-page":"16730","DOI":"10.1016\/S0021-9258(19)85478-9","article-title":"22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected t cells","volume":"268","author":"Inoue","year":"1993","journal-title":"J Biol Chem"},{"key":"2024020713274664000_bib15","first-page":"86","volume-title":"Bisphosphonates in Bone Disease: From the Laboratory to the Patient","author":"Fleisch","year":"1995"},{"key":"2024020713274664000_bib16","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/endo-128-4-1687","article-title":"On the mechanisms for the selective action of vitamin D analogs","volume":"128","author":"Dusso","year":"1991","journal-title":"Endocrinology"},{"key":"2024020713274664000_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.jbchem.a124346","article-title":"The binding properties, with blood proteins, and tissue distribution of 22-oxa-1\u03b1,25-dihydroxyvitamin D3, a noncalcemic analogue of 1\u03b1,25-dihydroxyvitamin D3, in rats","volume":"115","author":"Kobayashi","year":"1994","journal-title":"J Biochem"},{"key":"2024020713274664000_bib18","first-page":"765","article-title":"Vitamin D: New actions, new analogs, new therapeutic potential","volume":"13","author":"Bikle","year":"1992","journal-title":"Endocr Rev"},{"key":"2024020713274664000_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(93)90282-T","article-title":"Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages","volume":"95","author":"Nussbaum","year":"1993","journal-title":"Am J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.1998.13.9.1378","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/13\/9\/1378\/56597087\/5650130904.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/13\/9\/1378\/56597087\/5650130904.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:57:03Z","timestamp":1710341823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/13\/9\/1378-1383\/7514410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9,1]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[1998,9,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.1998.13.9.1378","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1998,9,1]]},"published":{"date-parts":[[1998,9,1]]}}}